Kazia Therapeutics Ltd

KZIA30 Nov 2024
Healthcare
$5.62
-0.05 (-5.31%)
Lowest Today
$5.16
Highest Today
$5.75
Today’s Open
$5.62
Prev. Close
$5.46
52 Week High
$15.8
52 Week Low
$1.87
To Invest in Kazia Therapeutics Ltd

Kazia Therapeutics Ltd

Healthcare
KZIA30 Nov 2024
-0.05 (-5.31%)
1M
3M
6M
1Y
5Y
Low
$5.16
Day’s Range
High
$5.75
5.16
52 Week Low
$1.87
52-Week Range
52 Week High
$15.8
1.87
1 Day
-
1 Week
-3.56%
1 month return
-3.22%
3 month return
+1143.67%
6 month return
+2108.16%
1 Year return
+818.5%
3 Years return
-47.62%
5 Years return
+28.19%
10 Years return
-
Institutional Holdings
Morgan Stanley - Brokerage Accounts
0.92
BNP Paribas Arbitrage, SA
0.15
Citadel Advisors Llc
0.14
Susquehanna International Group, LLP
0.1
Virtu Financial LLC
0.09
XTX Topco Ltd
0.05
UBS Group AG
0.05

Market Status

Fundamentals
Market Cap
23.78 mln
PB Ratio
3.09
PE Ratio
0
Enterprise Value
23.12 mln
Total Assets
21.58 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Organisation
Kazia Therapeutics Ltd
Employees
0
Industry
Biotechnology
CEO
Dr. John Edwin Friend II, M.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities